Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
FUSION PROTEIN COMPRISING ANTI-MESOTHELIN ANTIBODY, ANTI-CD3 ANTIBODY OR ANTI-EGFR ANTIBODY, BISPECIFIC OR TRISPECIFIC ANTIBODY COMPRISING SAME, AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/204305
Kind Code:
A1
Abstract:
The present invention relates to: a fusion protein comprising a fragment of an anti-mesothelin antibody, an anti-CD3 antibody or an anti-EGFR antibody; a bispecific antibody that is specific to mesothelin and CD3; a trispecific antibody that is specific to mesothelin, CD3 and EGFR; and uses thereof. The bispecific or trispecific antibody according to the present invention can be prepared in a high yield and with high purity, and has excellent tumor killing and growth inhibitory effects, and thus can be effectively used in cancer treatment.

Inventors:
LIM YANGMI (KR)
LEE SHINAI (KR)
WON JONGHWA (KR)
PARK YONG-YEA (KR)
YOON AERIN (KR)
LEE SUA (KR)
LIM OKJAE (KR)
LIM SOJUNG (KR)
KIM MUNKYUNG (KR)
Application Number:
PCT/KR2019/017809
Publication Date:
October 08, 2020
Filing Date:
December 16, 2019
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
GREEN CROSS CORP (KR)
MOGAM INST BIOMEDICAL RES (KR)
International Classes:
C07K16/28; A61K39/00; A61P35/00; C07K16/30
Domestic Patent References:
WO2018045090A12018-03-08
Foreign References:
KR20180037950A2018-04-13
US9416190B22016-08-16
KR20080077261A2008-08-21
US9708412B22017-07-18
Attorney, Agent or Firm:
FIRSTLAW P.C. (KR)
Download PDF: